239 related articles for article (PubMed ID: 12637589)
1. Vitamin D: more than a "bone-a-fide" hormone.
Sutton AL; MacDonald PN
Mol Endocrinol; 2003 May; 17(5):777-91. PubMed ID: 12637589
[TBL] [Abstract][Full Text] [Related]
2. Salt concentration determines 1,25-dihydroxyvitamin D3 dependency of vitamin D receptor-retinoid X receptor--vitamin D-responsive element complex formation.
Kimmel-Jehan C; Jehan F; DeLuca HF
Arch Biochem Biophys; 1997 May; 341(1):75-80. PubMed ID: 9143355
[TBL] [Abstract][Full Text] [Related]
3. Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation.
Bettoun DJ; Burris TP; Houck KA; Buck DW; Stayrook KR; Khalifa B; Lu J; Chin WW; Nagpal S
Mol Endocrinol; 2003 Nov; 17(11):2320-8. PubMed ID: 12893883
[TBL] [Abstract][Full Text] [Related]
4. A novel inborn error in the ligand-binding domain of the vitamin D receptor causes hereditary vitamin D-resistant rickets.
Malloy PJ; Zhu W; Zhao XY; Pehling GB; Feldman D
Mol Genet Metab; 2001 Jun; 73(2):138-48. PubMed ID: 11386849
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor displays DNA binding and transactivation as a heterodimer with the retinoid X receptor, but not with the thyroid hormone receptor.
Thompson PD; Hsieh JC; Whitfield GK; Haussler CA; Jurutka PW; Galligan MA; Tillman JB; Spindler SR; Haussler MR
J Cell Biochem; 1999 Dec; 75(3):462-80. PubMed ID: 10536369
[TBL] [Abstract][Full Text] [Related]
6. Retinoid X receptor isotype identity directs human vitamin D receptor heterodimer transactivation from the 24-hydroxylase vitamin D response elements in yeast.
Kephart DD; Walfish PG; DeLuca H; Butt TR
Mol Endocrinol; 1996 Apr; 10(4):408-19. PubMed ID: 8721985
[TBL] [Abstract][Full Text] [Related]
7. Ligand-triggered stabilization of vitamin D receptor/retinoid X receptor heterodimer conformations on DR4-type response elements.
Quack M; Carlberg C
J Mol Biol; 2000 Feb; 296(3):743-56. PubMed ID: 10677278
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner.
Whitfield GK; Selznick SH; Haussler CA; Hsieh JC; Galligan MA; Jurutka PW; Thompson PD; Lee SM; Zerwekh JE; Haussler MR
Mol Endocrinol; 1996 Dec; 10(12):1617-31. PubMed ID: 8961271
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin D receptor modulators.
Inaba Y; Yamamoto K; Yoshimoto N; Matsunawa M; Uno S; Yamada S; Makishima M
Mol Pharmacol; 2007 May; 71(5):1298-311. PubMed ID: 17325131
[TBL] [Abstract][Full Text] [Related]
10. New insights into the mechanisms of vitamin D action.
Christakos S; Dhawan P; Liu Y; Peng X; Porta A
J Cell Biochem; 2003 Mar; 88(4):695-705. PubMed ID: 12577303
[TBL] [Abstract][Full Text] [Related]
11. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes.
Staal A; van Wijnen AJ; Birkenhäger JC; Pols HA; Prahl J; DeLuca H; Gaub MP; Lian JB; Stein GS; van Leeuwen JP; Stein JL
Mol Endocrinol; 1996 Nov; 10(11):1444-56. PubMed ID: 8923469
[TBL] [Abstract][Full Text] [Related]
12. Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor.
Liu YY; Nguyen C; Peleg S
Mol Endocrinol; 2000 Nov; 14(11):1776-87. PubMed ID: 11075811
[TBL] [Abstract][Full Text] [Related]
13. [Vitamin D: implications for health and pregnancy].
Díaz L; Cariño C; Méndez I
Rev Invest Clin; 2001; 53(1):77-85. PubMed ID: 11332054
[TBL] [Abstract][Full Text] [Related]
14. Thyroid hormone receptor does not heterodimerize with the vitamin D receptor but represses vitamin D receptor-mediated transactivation.
Raval-Pandya M; Freedman LP; Li H; Christakos S
Mol Endocrinol; 1998 Sep; 12(9):1367-79. PubMed ID: 9731705
[TBL] [Abstract][Full Text] [Related]
15. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention.
Haussler MR; Haussler CA; Bartik L; Whitfield GK; Hsieh JC; Slater S; Jurutka PW
Nutr Rev; 2008 Oct; 66(10 Suppl 2):S98-112. PubMed ID: 18844852
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid.
Kane KF; Langman MJ; Williams GR
Cancer Res; 1996 Feb; 56(3):623-32. PubMed ID: 8564982
[TBL] [Abstract][Full Text] [Related]
18. Ligand occupancy is not required for vitamin D receptor and retinoid receptor-mediated transcriptional activation.
Matkovits T; Christakos S
Mol Endocrinol; 1995 Feb; 9(2):232-42. PubMed ID: 7776973
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators.
Issa LL; Leong GM; Sutherland RL; Eisman JA
J Bone Miner Res; 2002 May; 17(5):879-90. PubMed ID: 12009019
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements.
Staal A; Van Wijnen AJ; Desai RK; Pols HA; Birkenhäger JC; Deluca HF; Denhardt DT; Stein JL; Van Leeuwen JP; Stein GS; Lian JB
Endocrinology; 1996 May; 137(5):2001-11. PubMed ID: 8612541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
